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Abstract There has been a growing need for
standard Asian population guidelines for cardiac CT
and cardiac MR due to differences in culture,
healthcare system, ethnicity and disease prevalence.
The Asian Society of Cardiovascular Imaging, as the
only society dedicated to cardiovascular imaging in
Asia, formed a cardiac CT and cardiac MR guideline
working group in order to help Asian practitioners to
establish cardiac CT and cardiac MR services. In this
ASCI cardiac MR appropriateness criteria report, 23
Technical Panel members representing various Asian
countries were invited to rate 50 indications that
can frequently be encountered in clinical practice in
Asia. Indications were rated on a scale of 1–9 to
be categorized into ‘appropriate’ (7–9), ‘uncertain’
(4–6), or ‘inappropriate’ (1–3). According to median
scores of the 23 members, the ﬁnal ratings for indi-
cations were 24 appropriate, 18 uncertain and 8
inappropriate with 22 ‘highly-agreed’ (19 appropriate
and 3 inappropriate) indications. This report is
expected to have a signiﬁcant impact on the cardiac
Technical Panel Members of ASCI 2010 Cardiac MR
Appropriateness Criteria have been processed in Appendix.
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Abbreviations
ACCF American College of Cardiology
Foundation
ARVD Arrhythmogenic right ventricular dysplasia
ASCI Asian Society of Cardiovascular Imaging
ASD Atrial septal defect
CABG Coronary artery bypass graft
CAD Coronary artery disease
CCT Cardiac CT
CHD Coronary heart disease
CMR Cardiac MR
CT Computed tomography
CTCA CT coronary angiography
ECG Electrocardiogram
JCCT Journal of Cardiovascular Computed
Tomography
LV Left ventricle
MR Magnetic resonance
MRA MR angiography
MRCA MR coronary angiography
MRI MR imaging
PCI Percutaneous coronary intervention
RV Right ventricle
TEE Transesophageal echocardiography
VSD Ventricular septal defect
Introduction
Due to differences in culture, healthcare systems,
ethnicity [1], socioeconomic status [2] and disease
prevalence [3, 4], existing guidelines for cardiac
computed tomography (CT) and cardiac magnetic
resonance (MR) developed by western professional
societies are often not applicable in Asian countries. In
March 2009, the Asian Society of Cardiovascular
Imaging (ASCI), as the only society in Asia dedicated
solely to cardiovascular imaging, nominated 7 repre-
sentatives from different Asian countries to form a
working group to provide recommendations on cardiac
CTandcardiacMR.Detailedbackgroundofthisproject
has previously been described in the ASCI cardiac CT
criteria report, the ﬁrst publication from the working
group, which summarized the opinions of leading
cardiac CT practitioners in Asia on 51 indications [5].
As the second step, we present here the ASCI cardiac
MR appropriateness criteria. The purpose of this report
is to serve as a reference for Asian practitioners to
promote and improve their use of cardiac MR by
providing appropriateness ratings for common clinical
indications.
Methods
ASCI cardiac MR appropriateness criteria were devel-
oped through the same process as used for ASCI CT
appropriateness criteria published earlier this year [5].
Brieﬂy,weemployedthemodiﬁedDelphimethodwith
one-round data collection to evaluate the cardiac MR
appropriateness [6, 7]. A total of 25 panelists were
nominated[Japan6,Korea5,Taiwan4,China3,Hong
Kong (China) 3, Singapore 2, Thailand 2] by Working
Group members, and approved by the Working Group
with consensus.
In the development of the cardiac MR indications,
the Working Group members agreed to use the 33
cardiac MR indications provided by the ACCF 2006
appropriateness criteria as the framework [8]. Indica-
tions considered for the ASCI 2010 cardiac CT
appropriateness criteria were added and integrated to
derive 50 indications which were approved by the
Working Group. Among the 50 indications, 28 were in
commonwithACCF2006appropriatenesscriteriaand
39 were in common with ASCI 2010 CT appropriate-
ness criteria. Three indications [risk assessment in
general populations with low, moderate and high
coronary heart disease risk using coronary magnetic
resonance angiography (MRA)] were original indica-
tions of ASCI cardiac MR appropriateness criteria.
A questionnaire was emailed to the 25 Technical
Panel members. After completion, the questionnaires
were collected by the ASCI ofﬁce. The question-
naires were collected during a period between
October 13 and November 11, 2009. Please refer to
the online supplement for the complete questionnaire
(Online Supplement 1).
Deﬁnition of cardiac MR
There are a variety of techniques used for cardiac MR
[9]. Basic protocols might include cine magnetic
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123resonance imaging (MRI) for wall motionand delayed
gadolinium enhancement MRI for the assessment of
scar [10–19]. However, some may perform stress tests
routinely using either perfusion MRI with adenosine
[20, 21] or cine MRI with dobutamine [22, 23], while
others may consider coronary and non-coronary MRA
[24, 25] as important parts of cardiac MR examina-
tions.Moreover,differenttechniquescanbeutilizedto
assess certain aspects of cardiac morphology and
function [26–29]. Since cardiac MR is still an intense
ﬁeldofresearchanddevelopment,itisalsopossiblefor
appropriateness to be inﬂuenced by the availability of
newer scanners and more sophisticated imaging tech-
niques[30].Thus,theWorkingGroupdecidedtoleave
the deﬁnition of cardiac MR to the judgment of the
Technical Panel members. Resulting variations in
deﬁnitions might be an important reﬂection of the
current perspectives of the leading Asian cardiac MR
practitioners. In the questionnaire, the term ‘‘cardiac
MR’’ was deﬁned as including motion, stress and rest
perfusion, delayed gadolinium enhancement, ﬂow
measurement, black blood T2-weighted imaging, and
coronary MRA.
Rating system
The rating system used in this Asian survey is the
same as previously used in other appropriateness
criteria reports and ASCI CT appropriateness criteria.
The panelists were asked to assess whether the use of
cardiac MR for various indications was appropriate,
uncertain or inappropriate. The Technical Panel
scored each indication as follows:
Score 7–9: Appropriate test for the speciﬁc indi-
cation. Test is generally acceptable and a reason-
able approach for the listed indication.
Score 4–6: Uncertain for speciﬁc indication. Test
maybegenerallyacceptableandmaybeareasonable
approach for the indication. Uncertainty also implies
that more research or patient information or both are
needed to classify the indication deﬁnitively.
Score 1–3: Inappropriate test for speciﬁc indica-
tion. Test is not generally acceptable and is not a
reasonable approach for the indication.
Inapanelwith23–25members,‘highlyagreed’was
deﬁned as 7 or fewer panelists rating outside the three-
point region containing the median. ‘Disagreement’
was deﬁned as at least 8 panelists rating in either
extreme (1–3 and 7–9). Median values for each
indication served as the ﬁnal scoring if there was no
disagreement among Technical Panelists [5, 7, 8]. If
therewasdisagreement,theﬁnalappropriatenessscore
was set as uncertain regardless of the median.
Results
The questionnaires were emailed to the Technical
Panel members on October 13, 2009. Completed
questionnaires were returned from 23 members
[Japan 6, Korea 5, Taiwan 4, China 2, Hong Kong
(China) 2, Singapore 2, Thailand 2] by November 11.
Their specialties were radiology in 17 and cardiology
in 6. The years of experience in the cardiovascular
ﬁeld ranged from 4 to 26 years while the experience
of cardiac MR interpretation ranged from 300 to
3,000 examinations. For the cardiologists, the number
of percutaneous coronary interventions performed
range from 0 to 700 cases. The hospitals they were
working in included city hospitals, medical centers,
and university hospitals, with in-patient bed numbers
ranging from 440 to 5,600. The complete list of
Technical Panel members is provided at the begin-
ning of this report.
Among the indications rated by Technical Panel,
none showed disagreement. There were 24 appropri-
ate, 18 uncertain and 8 inappropriate indications.
Technical Panel members highly agreed in 22
indications, including 19 appropriate and 3 inappro-
priate indications. The ‘highly agreed’ inappropriate
indications were: use of cardiac MR for evaluation of
chest pain syndrome in patients with low pre-test
probabilities of CAD, interpretable ECGs and ability
to exercise; use of cardiac MR for detection of CAD
in asymptomatic patients with low coronary heart
disease risk; and use of coronary MRA for risk
assessment in patients with low coronary heart
disease risk. A detail appropriateness rating result is
provided as an online supplement (Online Supple-
ment 2).
Compared with the ACCF 2006 report [8], only 4/
28 (14%) indications changed their category. Indica-
tion no. 38 (‘‘evaluation of LV function following
myocardial infarction or in heart failure patients’’)
and no. 49 (‘‘to detect post PCI myocardial necrosis’’)
were shifted from uncertain to appropriate. Indication
no. 30 (‘‘evaluation of bypass grafts and coronary
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123anatomy’’) and no. 31 (‘‘history of percutaneous
revascularization with stents’’) were shifted from
inappropriate to uncertain.
Compared with the ASCI cardiac CT appropriate-
ness criteria report [5], 29/39 (74%) were in the same
appropriateness category. In 7 indications, cardiac CT
received a more favorable category than cardiac MR:
indication no. 2 (‘‘detection of CAD: symptomatic,
intermediate pre-test probability of CAD. ECG
interpretable and able to exercise’’), no. 27 (‘‘use of
MRI for CAD evaluation before valve surgery’’), no.
29 (‘‘evaluation of complex lesions before PCI’’), no.
30 (‘‘evaluation of bypass grafts and coronary
anatomy’’), no. 31 (‘‘history of percutaneous revas-
cularization with stents’’), no. 33 (‘‘evaluation of
bypass grafts and coronary anatomy greater than or
equal to 5 years after CABG’’), and no. 34 (‘‘eval-
uation for in-stent restenosis and coronary anatomy
after PCI’’). On the other hand, cardiac MR received
a more favorable category than cardiac CT in 3
indications; indication no. 38 (‘‘evaluation of LV
function following myocardial infarction or in heart
failure patients’’), no. 48 (‘‘to determine the location
and extent of myocardial infarction including ‘no-
reﬂow’ regions, post-acute myocardial infarction’’),
and no. 50 (‘‘to determine viability prior to revascu-
larization’’).
The ﬁnal ratings for cardiac MR are listed by
indication sequentially (Tables 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11) and by appropriateness category (Tables 12,
13, 14).
Discussion
This ASCI cardiac MR appropriateness criteria report
was developed in order to reﬂect the current status of
cardiac MR in Asia and the opinions of Asian cardiac
MR leaders about appropriate indications for cardiac
MR. This report should prove useful in clinical
Table 1 Detection of
CAD: symptomatic
Indication Appropriateness
criteria
(median score)
Note
Evaluation of chest pain syndrome
1 Low pre-test probability of CAD I (2) Highly agreed
ACCF indication no. 1 ECG interpretable AND able to exercise
2 Intermediate pre-test probability of CAD U (4) ACCF indication no. 2
ECG interpretable AND able to exercise ASCI CT indication no. 1
3 Intermediate pre-test probability of CAD A (7) ACCF indication no. 3
ECG uninterpretable OR unable to exercise ASCI CT indication no. 2
4 High pre-test probability of CAD U (6) ACCF indication no. 4
ASCI CT indication no. 3
Evaluation of intra-cardiac structures
5 Evaluation of suspected coronary anomalies A (8) Highly agreed
ACCF indication no. 8
ASCI CT indication no. 4
Acute chest pain
6 Low pre-test probability of CAD U (4) ASCI CT indication no. 5
No ECG changes and serial enzymes negative
7 Intermediate pre-test probability of CAD U (5) ACCF indication no. 9
No ECG changes and serial enzymes negative ASCI CT indication no. 6
8 High pre-test probability of CAD U (5) ASCI CT indication no. 7
No ECG changes and serial enzymes negative
9 High pre-test probability of CAD I (2) ACCF indication no. 10
ECG—ST-segment elevation and/or
positive cardiac enzymes
ASCI CT indication no. 8
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123practice in Asia, especially for institutes starting
cardiac MR services for the ﬁrst time.
Among the 50 indications evaluated in this report,
28 were in common with the ACCF 2006 appropri-
ateness criteria report [8], 39 were also included in
the ASCI 2010 cardiac CT appropriateness criteria
report [5] and 3 indications were unique to this report.
In contrast to the ASCI cardiac CT appropriateness
criteria report in which an upward shift of appropri-
ateness category was demonstrated in 51.3% (20/39)
of the indications as compared with ACCF 2006
appropriateness criteria report, such a shift was seen
in only 14.3% (4/28) of the indications in this cardiac
MR appropriateness criteria report. The rapid
advancement of CT technology [31] and associated
accumulation of evidence of its clinical usefulness
[32–34] as well as reduction of its radiation levels
[32] may explain the faster expansion of appropriate
indications for cardiac CT compared to the expansion
seen for cardiac MR, which has seen comparatively
few technical advances over the past 5 years.
One of the most signiﬁcant features of the ASCI
cardiac CT and cardiac MR appropriateness criteria
reports is the high number of indications evaluated for
both CT and MR. Although cardiac CT was originally
developedforvisualizationofcoronaryanatomy,recent
studies have demonstrated the potential usefulness of
one-stop shop cardiac examination in assessment of
function,myocardialischemia andmyocardialviability
[35, 36]. Meanwhile, the introduction of whole heart
coronaryMRAhasenabledroutineimagingofcoronary
anatomy which is completely noninvasive and without
the need for radiation exposure and contrast medium
[24, 37, 38]. Given the similarities in information
obtainable, it is inevitable that CT and MR share many
indications. In our questionnaire surveys, different
panelists were selected for CT and MR. The panelists
were not aware that similar surveys were being
performed for the other modality, thus minimizing the
extent to which their ratings were based on comparison
tothe other modality.Our surveydemonstrated thatCT
received higher ratings than MR in the morphological
assessmentofnativecoronaryarteriesandbypassgrafts
before and after revascularization therapy. On the other
hand, assessment of myocardial viability and ﬁbrosis
can be performed better with MR. However, most
appropriateness ratings were similar for CT and MR,
indicating that modality choice should be based on the
technology and expertise available at each individual
medical center.
‘‘Use of coronary MRA in the risk assessment of
general population’’ was evaluated in this survey.
This indication was evaluated because coronary
MRA has been gaining popularity as a screening
tool in recent years, since the introduction of whole-
heart coronary MRA [37, 39]. We found that
experts in Asia consider this indication inappropri-
ate in populations with low to intermediate coronary
heart disease risk. Future research is needed to
determine whether risk assessment of population
with high coronary heart disease risk is appropriate
or not.
This survey had several limitations. As was the
case with the ASCI cardiac CT appropriateness
criteria report, the Technical Panel in this study was
dominated by experts from Eastern and Southeastern
Table 2 Detection of
CAD: asymptomatic
(without chest pain
syndrome)
Indication Appropriateness
criteria
(median score)
Note
Asymptomatic
10 Low CHD risk (Framingham
risk criteria)
I (1) Highly agreed
ASCI CT indication no. 10
11 Moderate CHD risk (Framingham) U (4) ASCI CT indication no. 11
12 High CHD risk (Framingham) U (6) ASCI CT indication no. 12
Table 3 Risk assessment: general population
Indication Appropriateness
criteria
(median score)
Note
Asymptomatic (use of coronary MRA)
13 Low CHD risk (Framingham) I (3) Highly
agreed
14 Moderate CHD risk
(Framingham)
I (3)
15 High CHD risk (Framingham) U (5)
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123Asia reﬂecting the current academic contribution and
participation in ASCI. We hope to see active
participation in ASCI from Asian countries outside
the Asia–Paciﬁc region in the future. Secondly, many
Technical Panelists proposed further clariﬁcation of
the scan protocol. Although the importance of correct
choice of MR scan protocol cannot be underesti-
mated, this aspect is considered too complicated to be
included in this questionnaire survey because of the
diversity and rapid innovation of MR scan techniques
Table 4 Detection of CAD
with prior test results
Indication Appropriateness
criteria
(median score)
Note
Evaluation of chest pain syndrome
16 Uninterpretable or equivocal stress test
(exercise, perfusion, or stress echo)
A (8) Highly agreed
ASCI CT indication no. 16
17 Evidence of moderate to severe ischemia
on stress test (exercise, perfusion,
or stress echo)
U (5) ASCI CT indication no. 17
Table 5 Risk assessment
with prior test results
Indication Appropriateness
criteria
(median score)
Note
Asymptomatic
18 Normal prior stress test (exercise, nuclear, echo,
MRI)
I (3) ACCF indication no.
11
High CHD risk (Framingham)
19 Equivocal stress test (exercise, stress SPECT, or
stress echo)
U (6) ACCF indication no.
12
Intermediate CHD risk (Framingham)
20 Coronary angiography (catheterization or CT) A (7) ACCF indication no.
13 Stenosis of unclear signiﬁcance
Table 6 CAD detection in
pediatric patients with
kawasaki disease
Indication Appropriateness
criteria
(median score)
Note
Asymptomatic
21 No previous deﬁnitive test
(invasive angiography, MRCA or CTCA)
available
U (5) Asian characteristic
indication
ASCI CT indication no. 21
22 Previous tests (invasive angiography,
CMR or CCT) documented coronary
aneurysm/stenosis, for follow up
A (7) Highly agreed
Asian characteristic
indication
ASCI CT indication no. 22
Symptomatic
23 No previous deﬁnitive test (invasive
angiography, MRCA or CTCA) available
A (7) Asian characteristic
indication
ASCI CT indication no. 23
24 Previous tests (angiography, CMR or CCT)
documented coronary aneurysm/stenosis,
for follow up
A (7) Asian characteristic
indication
ASCI CT indication no. 24
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123Table 7 Risk assessment:
preoperative evaluation for
non-cardiac surgery
Indication Appropriateness
criteria
(median score)
Note
Low-risk surgery
25 Intermediate perioperative risk I (3) ACCF indication no. 14
ASCI CT indication no. 25
Intermediate- or high-risk surgery
26 Intermediate perioperative risk U (5) ACCF indication no. 15
ASCI CT indication no. 26
Table 8 Risk assessment:
preoperative evaluation for
cardiac surgery or
endovascular intervention
Indication Appropriateness
criteria
(median score)
Note
Preoperative evaluation
27 Use of MRI for CAD evaluation
before valve surgery
U (6) JCCT 2009 proposed
indication
ASCI CT indication no. 27
28 Anatomic assessment before percutaneous
device closure of ASD or VSD or
percutaneous aortic valve replacement
A (7) JCCT 2009 proposed
indication
ASCI CT indication no. 28
29 Evaluation of complex lesions before PCI
(i.e., chronic total occlusions, bifurcation
lesions)
U (5) JCCT 2009 proposed
indication
ASCI CT indication no. 29
Table 9 Detection of
CAD: post-
revascularization (PCI or
CABG)
Indication Appropriateness
criteria
(median
score)
Note
Evaluation of chest pain syndrome
30 Evaluation of bypass grafts
and coronary anatomy
U (5) ACCF indication no.
16
ASCI CT indication
no. 30
31 History of percutaneous
revascularization with stents
U (4) ACCF indication no.
17
ASCI CT indication
no. 31
Asymptomatic
32 Evaluation of bypass grafts and coronary
anatomy
U (4) ASCI CT indication
no. 32
Less than 5 years after CABG
33 Evaluation of bypass grafts and coronary anatomy U (4) ASCI CT indication
no. 33 Greater than or equal to 5 years after CABG
34 Evaluation for in-stent restenosis and coronary
anatomy after PCI
I (3) ASCI CT indication
no. 34
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123used for cardiac examinations. Third, the comparison
of CT and MR in the discussion section was done
based on separate surveys. Since the panelists were
not aware of the potential comparison, the compar-
ison is not a ‘head-to-head’ comparison. Rather, the
comparison is actually ‘what indications cardiac CT
Table 10 Structure and function
Indication Appropriateness
criteria (median
score)
Note
Morphology
35 Assessment of complex congenital heart disease including anomalies of
coronary circulation, great vessels, and cardiac chambers and valves
A (8) Highly agreed
ACCF indication no. 18
ASCI CT indication no. 35
36 Assessment of post-operative congenital heart disease, such as residual
pulmonary stenosis, ventricular septal defect and patency check for
Blalock-Taussig shunt
A (8) Highly agreed
ASCI CT indication no. 36
Asian characteristic indication
37 Evaluation in patients with new onset heart failure to assess etiology A (8) Highly agreed
ASCI CT indication no. 37
Evaluation of ventricular and valvular function
38 Evaluation of LV function following myocardial infarction OR in heart
failure patients
A (8) Highly agreed
ACCF indication no. 19
39 Evaluation of LV function following myocardial infarction OR in heart
failure patients
A (9) Highly agreed
ACCF indication no. 20
Patients with technically limited images from echocardiogram
40 Quantiﬁcation of LV function A(9) Highly agreed
Discordant information that is clinically signiﬁcant from prior tests ACCF indication no. 21
41 Evaluation of speciﬁc cardiomyopathies (inﬁltrative [amyloid, sarcoid],
HCM, or due to cardiotoxic therapies)
A(9) Highly agreed
ACCF indication no. 22
42 Characterization of native and prosthetic cardiac valves A (7) Highly agreed
Patients with technically limited images from echocardiogram or TEE ACCF indication no. 23
43 Evaluation for arrhythmogenic right ventricular cardiomyopathy
(ARVC)
A (8) Highly agreed
ACCF indication no. 24
Patients presenting with syncope or ventricular arrhythmia
44 Evaluation of myocarditis or myocardial infarction with normal coronary
arteries
A(9) Highly agreed
ACCF indication no. 25
Positive cardiac enzymes without obstructive atherosclerosis on
angiography
Evaluation of intra- and extra-cardiac structures
45 Evaluation of cardiac mass (suspected tumor or thrombus) A (9) Highly agreed
Patients with technically limited images from echocardiogram or TEE ACCF indication no. 26
ASCI CT indication no. 42
46 Evaluation of pericardial conditions (pericardial mass, constrictive
pericarditis, or complications of cardiac surgery)
A (8) Highly agreed
Patients with technically limited images from echocardiogram or TEE ACCF indication no. 27
ASCI CT indication no. 43
47 Evaluation of pulmonary vein anatomy prior to invasive radiofrequency
ablation for atrial ﬁbrillation
A (7) Highly agreed
ACCF indication no. 29
Left atrial and pulmonary venous anatomy including dimensions of veins
for mapping purposes
ASCI CT indication no. 44
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123experts think are appropriate for cardiac CT’ vs ‘what
indications cardiac MR experts think are appropriate
for cardiac MR’. Although such comparison still
gives us some reasonable insights on the appropriate
choice of modality, ‘head-to-head’ comparison might
be more desirable for appropriate use of cardiac CT
and cardiac MR. However, in order to perform a
‘head-to-head’ comparison, we would need to subdi-
vide the indications based on the patient’s age, sex,
renal function, allergy to the contrast medium etc.,
which would run the risk of making the guidelines
overly lengthy and complicated.
We expect that this ASCI 2010 cardiac MR
appropriateness criteria report will serve as a timely
and useful guide for the establishment of clinical
cardiac MR services in Asian countries. ASCI will
continue to pay close attention to this ﬁeld and keep
Asian practitioners updated about developments in
cardiac MR and new indications as they arise.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction
in any medium, provided the original author(s) and source are
credited.
Appendix
Ping Chai, MRCP (Cardiac Department, National
University Heart Centre, Singapore), Anna K Chan,
MB ChB (Department of Medicine and Therapeutics,
Prince of Wales Hospital, The Chinese University of
Hong Kong, Hong Kong, China), Liuquan Cheng,
MD, PhD (Department of Radiology, Chinese PLA
General Hospital, Beijing, China), Yeon Hyeon
Choe, MD, PhD (Department of Radiology, Samsung
Medical Center, Sungkyunkwan University School of
Medicine, Seoul, Korea), Sang Il Choi, MD, PhD
(Department of Radiology, Seoul National University
Bundang Hospital, Seongnam, Korea), Yuen Chi Ho,
MBBS, FRCR, FHKCR (Department of Radiology,
Queen Mary Hospital, Hong Kong, China), John
Huang, MB ChB, MRCP, FRCR (Department of
Diagnostic Radiology, Singapore General Hospital,
Singapore), Gham Hur, MD, PhD (Departments of
Diagnostic Radiology, Inje University Ilsanpaik
Hospital, Korea), Yasutaka Ichikawa, MD (Depart-
ment of Radiology, Matsusaka Central Hospital,
Matsusaka, Japan), Misako Iino, MD, PhD (Depart-
ment of Radiology, Tokai University Hospital, Ise-
hara, Japan), Shuichiro Kaji, MD, PhD (Department
of Cardiovascular Medicine, Kobe City Medical
Center General Hospital, Kobe, Japan), Tae Hoon
Kim, MD (Department of Radiology, Gangnam Sev-
erance Hospital, Yonsei University, Seoul, Korea),
Sheung-Fat Ko, MD (Department of Radiology,
Chang Gung university, College of Medicine, Chang
Gung Memorial Hospital-Kaohsiung Medical Center,
Kaohsiung, Taiwan), Yasuyuki Kobayashi, MD
(Department of Radiology, St. Marianna University
School of Medicine, Kawasaki, Japan), Rungroj
Krittayaphong, MD, FACC, FESC (Division of
Cardiology, Department of Medicine, Siriraj Hospi-
tal, Bangkok, Thailand), Jongmin Lee, MD, PhD
(Department of Radiology, Kyungpook National
University Hospital, Daegu, Korea), Whal Lee, MD
(Department of Radiology, Seoul National University
Hospital, Seoul, Korea), Noiko Oyama, MD, PhD
(Department of Radiology, Hokkaido University
Hospital, Sapporo, Japan), Pairoj Rerkpattanapipat,
Table 11 Detection of
myocardial scar and
viability
Indication Appropriateness
criteria
(median score)
Note
Evaluation of myocardial scar
48 To determine the location and extent of
myocardial infarction including
‘no-reﬂow’ regions
A (9) Highly agreed
ACCF indication no. 30
Post-acute myocardial infarction
49 To detect post PCI myocardial necrosis A (8) Highly agreed
ACCF indication no. 31
50 To determine viability
prior to revascularization
A (9) Highly agreed
ACCF indication no. 32
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123Table 12 Appropriate indications (median score 7–9)
Indication Appropriateness
criteria
(median score)
Detection of CAD: symptomatic—evaluation of chest pain syndrome
3 Intermediate pre-test probability of CAD A (7)
ECG uninterpretable OR unable to exercise
Detection of CAD: symptomatic—evaluation of intra-cardiac structures
5 Evaluation of suspected coronary anomalies A (8)
Detection of CAD with prior test results—evaluation of chest pain syndrome
16 Uninterpretable or equivocal stress test (exercise, perfusion, or stress echo) A (8)
Risk Assessment with prior test results—asymptomatic
20 Coronary angiography (catheterization or CT) A (7)
Stenosis of unclear signiﬁcance
CAD detection in pediatric patients with kawasaki disease—asymptomatic
22 Previous tests (invasive angiography, CMR or CCT) documented coronary
aneurysm/stenosis, for follow up
A (7)
CAD detection in pediatric patients with kawasaki disease—symptomatic
23 No previous deﬁnitive test (invasive angiography, MRCA or CTCA) available A (7)
24 Previous tests (angiography, CMR or CCT) documented coronary
aneurysm/stenosis, for follow up
A (7)
Risk Assessment: preoperative evaluation for cardiac surgery or endovascular intervention—preoperative evaluation
28 Anatomic assessment before percutaneous device closure
of ASD or VSD or percutaneous aortic valve replacement
A (7)
Structure and function—morphology
35 Assessment of complex congenital heart disease including
anomalies of coronary circulation, great vessels, and cardiac chambers and valves
A (8)
36 Assessment of post-operative congenital heart disease, such
as residual pulmonary stenosis, ventricular septal defect and patency
check for Blalock-Taussig shunt
A (8)
37 Evaluation in patients with new onset heart failure to assess etiology A (8)
Structure and function—evaluation of ventricular and valvular function
39 Evaluation of LV function following myocardial infarction OR in heart failure patients A (9)
Patients with technically limited images from echocardiogram
38 Evaluation of LV function following myocardial infarction OR in heart failure patients A (8)
40 Quantiﬁcation of LV function A(9)
Discordant information that is clinically signiﬁcant from prior tests
41 Evaluation of speciﬁc cardiomyopathies (inﬁltrative [amyloid,
sarcoid], HCM, or due to cardiotoxic therapies)
A(9)
42 Characterization of native and prosthetic cardiac valves A (7)
Patients with technically limited images from echocardiogram or TEE
43 Evaluation for arrhythmogenic right ventricular cardiomyopathy (ARVC) A (8)
Patients presenting with syncope or ventricular arrhythmia
44 Evaluation of myocarditis or myocardial infarction with normal coronary arteries A(9)
Positive cardiac enzymes without obstructive atherosclerosis on angiography
Structure and function—evaluation of intra- and extra-cardiac structures
45 Evaluation of cardiac mass (suspected tumor or thrombus) A (9)
Patients with technically limited images from echocardiogram or TEE
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123Table 13 Uncertain indications (median score 4–6)
Indication Appropriateness
criteria (median score)
Detection of CAD: symptomatic—evaluation of chest pain syndrome
2 Intermediate pre-test probability of CAD U (4)
ECG interpretable AND able to exercise
4 High pre-test probability of CAD U (6)
Detection of CAD: symptomatic—acute chest pain
6 Low pre-test probability of CAD U (4)
No ECG changes and serial enzymes negative
7 Intermediate pre-test probability of CAD U (5)
No ECG changes and serial enzymes negative
8 High pre-test probability of CAD U (5)
No ECG changes and serial enzymes negative
Detection of CAD: asymptomatic—asymptomatic
11 Moderate CHD risk (Framingham) U (4)
12 High CHD risk (Framingham) U (6)
Risk Assessment: general population—asymptomatic (use of coronary MRA)
15 High CHD risk (Framingham) U (5)
Detection of CAD with prior test results—evaluation of chest pain syndrome
17 Evidence of moderate to severe ischemia on stress test (exercise, perfusion, or stress echo) U (5)
Risk Assessment with prior test results—asymptomatic
19 Equivocal stress test (exercise, stress SPECT, or stress echo) U (6)
Intermediate CHD risk (Framingham)
CAD detection in pediatric patients with kawasaki disease—asymptomatic
21 No previous deﬁnitive test (invasive angiography, MRCA or CTCA) available U (5)
Risk assessment: preoperative evaluation for non-cardiac surgery
Intermediate- or high-risk surgery
26 Intermediate perioperative risk U (5)
Risk assessment: preoperative evaluation for cardiac surgery or endovascular intervention—preoperative evaluation
27 Use of MRI for CAD evaluation before valve surgery U (6)
Table 12 continued
Indication Appropriateness
criteria
(median score)
46 Evaluation of pericardial conditions (pericardial mass, constrictive pericarditis, or complications of cardiac
surgery)
A (8)
Patients with technically limited images from echocardiogram or TEE
47 Evaluation of pulmonary vein anatomy prior to invasive radiofrequency ablation for atrial ﬁbrillation A (7)
Left atrial and pulmonary venous anatomy including dimensions of veins for mapping purposes
Structure and function—evaluation of myocardial scar
48 To determine the location and extent of myocardial infarction including ‘no-reﬂow’ regions A (9)
Post-acute myocardial infarction
49 To detect post PCI myocardial necrosis A (8)
50 To determine viability prior to revascularization A (9)
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123MD, FACC, FACP, FASE. (Division of Cardiovas-
cular Disease, Department of Medicine, Ramathibodi
Hospital, Mahidol University, Thailand and Frye
Heart Center, USA), Kunihiko Teraoka, MD, PhD
(Department of Cardiology, Tokyo Medical Univer-
sity, Hachioji Medical Center, Hachioji, Japan), Wen-
Yih Isaac Tseng, MD, PhD (Department of Medical
Imaging, National Taiwan University Hospital, Tai-
pei, Taiwan), Ming-Ting Wu, MD (Department of
Radiology, Faculty of Medicine, School of Medicine,
National Yang Ming University, Taipei, Taiwan),
Chun-Ho Yun, MD (Department of Radiology,
Table 14 Inappropriate
indications (median score
1–3)
Indication Appropriateness
criteria
(median score)
Detection of CAD: symptomatic—evaluation of chest pain syndrome
1 Low pre-test probability of CAD I (2)
ECG interpretable AND able to exercise
Detection of CAD: symptomatic—acute chest pain
9 High pre-test probability of CAD I (2)
ECG—ST-segment elevation and/or positive cardiac enzymes
Detection of CAD: asymptomatic (without chest pain syndrome)—asymptomatic
10 Low CHD risk (Framingham risk criteria) I (1)
Risk assessment: general population—asymptomatic (use of coronary MRA)
13 Low CHD risk (Framingham) I (3)
14 Moderate CHD risk (Framingham) I (3)
Risk assessment with prior test results—asymptomatic
18 Normal prior stress test (exercise, nuclear, echo, MRI) I (3)
High CHD risk (Framingham)
Risk assessment: preoperative evaluation for non-cardiac surgery—low-risk surgery
25 Intermediate perioperative risk I (3)
Detection of CAD: post-revascularization (PCI or CABG)—asymptomatic
34 Evaluation for in-stent restenosis and coronary anatomy after PCI I (3)
Table 13 continued
Indication Appropriateness
criteria (median score)
29 Evaluation of complex lesions before PCI (i.e., chronic total occlusions, bifurcation lesions) U (5)
Detection of CAD: post-revascularization (PCI or CABG)—evaluation of chest pain syndrome
30 Evaluation of bypass grafts and coronary anatomy U (5)
31 History of percutaneous revascularization with stents U (4)
Detection of CAD: post-revascularization (PCI or CABG)—asymptomatic
32 Evaluation of bypass grafts and coronary anatomy U (4)
Less than 5 years after CABG
33 Evaluation of bypass grafts and coronary anatomy U (4)
Greater than or equal to 5 years after CABG
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123Mackay Memorial Hospital, Taipei, Taiwan), Shihua
Zhao, MD (Department of Radiology, Cardiovascular
Institute and Fuwai Hospital, Peking Union Medical
University and Chinese Academy of Medical Sci-
ence, Beijing, China).
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